The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson’s Disease by Alkanli, Nevra & Ay, Arzu
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
The Relationship between 
Alpha-Synuclein (SNCA) Gene 
Polymorphisms and Development 
Risk of Parkinson’s Disease
Nevra Alkanli and Arzu Ay
Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder affecting the motor 
system and occurring in the central nervous system. One of the symptoms of PD 
is accumulation of Lewy bodies and Lewy neurites. The alpha-synuclein (SNCA) 
gene is part of the protein complex called Lewy body. The SNCA gene encoding 
a presynaptic protein product is thought to play a role in PD-related important path-
ways. It is suggested that there is a relationship between the risk of PD development 
and SNCA levels, and it is suggested that SNCA level is an important marker in 
PD diagnosis. Various polymorphisms have been identified in the 5′ and/or 3′ UTR 
regions of the SNCA gene, and as a result of these polymorphisms, changes occur 
in the binding of transcription factors. The identification of the roles of SNCA gene 
polymorphisms in PD development may enable the development of new methods 
for the treatment of PD.
Keywords: Parkinson’s disease, neurodegenerative disorders, SNCA gene 
polymorphisms, Lewy bodies, SNCA levels
1. Introduction
The most important feature of age-related neurodegenerative diseases is the 
slow and irreversible deterioration of brain function. PD affects the motor sys-
tem and is a neurodegenerative disorder of the central nervous system [1]. The 
prevalence of PD, which is known to be the second progressive neurodegenera-
tive disease, increases with age. PD, which causes severe morbidity, has motor 
symptoms such as tremors, bradykinesia, muscle stiffness, and postural instability 
and non-motor symptoms, i.e., autonomic dysfunction, sensory symptoms, sleep 
disturbances, and fatigue. These symptoms occur as a result of the progressive 
neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta, 
clustering of proteins within the brain, Lewy bodies, and Lewy neurites [2, 3]. As 
a result of degeneration of dopaminergic neurons, movement disorder occurs, and 
the cause of this movement disorder is the neurotransmitter dopamine deficiency. 
Although the basic mechanism of neuronal death in PD is unknown, genetic and 
environmental factors have been found to be effective in the pathogenesis of the 
disease [4].
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It has been reported that many genes play a role in the pathogenesis of PD, and 
polymorphisms in these genes may be genetic risk factors for PD development [5]. 
A large number of different DNA variants have been identified in disease genes 
associated with familial PD in molecular genetic analyses. These genetic variants 
include SNCA, Parkin (PARK2), PTEN-induced putative kinase 1 (PINK1), DJ-1 
(PARK7), and leucine-rich repeat kinase 2 (LRRK2) variants [6].
The SNCA gene plays a role in important pathways associated with PD. It is sug-
gested that there is a significant relationship between SNCA levels and the risk of PD 
development, and SNCA levels are thought to be an important marker in the diag-
nosis of PD. Several studies have been conducted to explain the relationship between 
genetic polymorphisms in different regions of the SNCA gene and risk of PD [7].
Polymorphisms that occur in different regions of the SNCA gene, an important 
gene for PD etiology, have been identified in relation to PD [7, 8]. Changes in SNCA 
expression levels are one of the main mechanisms of SNCA to cause PD [7, 9, 10]. 
As a result of polymorphisms in the 5′ and 3′ UTR regions of the SNCA gene, the 
binding of transcription factors and miRNAs can be altered, and promoter activity 
is affected. Thus, gene expression can be regulated. According to the general results 
from the studies aimed to investigate the relationship between SNCA gene polymor-
phisms and the risk of PD development, the SNCA gene and some polymorphisms 
of this gene have been identified as genetic risk factors in PD development [7].
The purpose of this chapter is, in addition to giving general information about 
PD, to summarize the studies that investigated on the relationship between SNCA 
gene polymorphisms and the risk of developing PD.
2. Parkinson’s disease
Parkinson’s disease (PD), the second most common neurodegenerative disease 
after Alzheimer’s disease, affects approximately 1–2% of individuals over 65 years 
of age [11, 12]. The incidence of PD usually begins after 50 years of age and 
increases more after 60 years of age [13]. The prevalence of PD increases approxi-
mately 4% in people over 85 years of age [6]. PD is a neurological disorder associ-
ated with increased morbidity and reduced survival [14, 15].
PD is characterized by bradykinesia, resting tremor, rigidity, and postural 
instability. PD is associated with the formation of Lewy bodies [16]. Lewy bodies of 
postmortem that are determined in brain autopsy specimens are the distinguishing 
features of PD. These bodies are observed in intense eosinophilic nuclei and cyto-
plasmic inclusions. The presence of intraneuronal protein inclusions, called Lewy 
bodies or Lewy neurites, is one of the neuropathological features of PD [17].
In PD, in addition to motor symptoms, non-motor symptoms occur. Motor 
symptoms in PD are due to the selective loss of dopaminergic neurons in the mid-
brain and the axon terminals reflected in the dorsal striatum [18]. Motor symptoms 
occur when neuronal cell loss reaches 80% or more as a result of progressive loss 
in the dopaminergic neurons of substantia nigra pars compacta [19]. Non-motor 
symptoms of PD are autonomic dysfunction and cognitive impairment [20]. The 
motor and non-motor symptoms of PD are caused by the loss of the dopaminergic 
neurons of the substantia nigra [21–23]. PD is defined as a syndrome because it is a 
complex disease characterized by motor and non-motor symptoms [20].
The majority of PD cases are sporadic cases; however, it is known that 10–15% 
are familial cases, and the majority of these cases are hereditary. Environmental and 
genetic factors play a role together in the pathogenesis of PD, which has a complex 
etiology [24].
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3. Protein encoded by SNCA gene
SNCA protein is the major protein of Lewy bodies. This protein is a presynaptic 
phosphoprotein that has a specific tendency to aggregation that plays an important 
role in both hereditary and idiopathic PD [25]. SNCA protein and fibrils constitute 
Lewy bodies [16]. In Lewy bodies, SNCA protein is predominant and is therefore 
known to be associated with the etiology of PD. SNCA also has an important func-
tion in the pathological process of PD [26, 27]. SNCA, an important component of 
Lewy bodies, is one of the distinctive features of PD [28–30].
The SNCA protein, which contains 144 amino acids, found as a soluble protein, 
not naturally folded in the cytoplasm, is encoded by three different SNCA tran-
scripts. The function of the SNCA protein in the brain is still not fully elucidated, 
but it has been found to play an important role in the neurotransmitter release 
and vesicle cycle at presynaptic terminals [6]. SNCA plays an important role in 
the regulation of neurotransmitter release, synaptic function, and plasticity of 
dopaminergic neurons [31–33].
Dopamine from presynaptic vesicles plays an important role in the normal 
functioning of a presynaptic complex [34–36]. Function of the SNCA protein, 
which is highly expressed in the brain; is the vesicle formation required for storage 
and transport of dopamine. Dopamine transported from the presynaptic neuron  
to the postsynaptic neuron is important for smooth and coordinated movements 
of the body. As a result of mutations in the SNCA protein, the vesicle that required 
for the dopamine transport cannot form, and the aggregates are formed. These 
aggregates are identified as important distinguishing features in PD pathogenesis. 
Genetic changes known to be effective in PD pathogenesis disrupt normal function 
of SNCA protein [37, 38].
4. Gene of SNCA
The SNCA gene is localized on the fourth chromosome in the human genome. 
It is the first gene associated with PD that contains a pathogenic missense mutation 
(Ala53Thr) responsible for the disease in a large Italian family [6]. The SNCA gene 
plays a role in important pathways associated with PD and encodes the presynaptic 
protein product. Therefore, this gene is one of the genes that are extensively studied 
among PD susceptibility genes [39].
It is the first causal gene in familial PD, and it encodes SNCA with main compo-
nent of Lewy bodies. Lewy bodies accumulate in neural cells in familial PD cases. 
The reason of this accumulation is overproduction of SNCA. Overproduction of 
normal SNCA also plays an important role in the pathogenesis of sporadic PD [40].
The chromosomal location is presented in Figure 1.
Figure 1. 
Chromosomal location of SNCA gene [41].
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5. Gene polymorphisms of SNCA
Genetic predisposition plays an important role in the etiology of PD. Multiple 
linkage and genome-wide association studies (GWAS) were performed to 
determine genetic polymorphisms in the SNCA gene. Single-nucleotide gene 
polymorphisms in the SNCA gene were found to be associated with increased PD 
risk. Single-nucleotide polymorphisms in the SNCA gene can lead to a change in 
PD susceptibility, resulting in increased or decreased PD risk. Several genes and 
several polymorphisms of the SNCA gene have been identified in GWAS. It has been 
determined that some of these gene polymorphisms may be important risk factors 
especially for sporadic PD [26]. Polymorphisms in different regions of the SNCA 
gene have been studied in various studies with different populations [7]. Genetic 
risk factors are very important in the development of PD, and up to now, 16 loci 
have been identified, which are known to be associated with the development of 
PD. Very few of the PD, which is mostly sporadic, are familial. The cause of familial 
PD development is autosomal recessive or dominant mutations. In particular, muta-
genic mutations (SNCA, LRRK2, PRKN, DJ-1, and PINK1) occurring in five genes 
were found to be related to familial PD. Six loci such as MAPT, SNCA, HLA-DRBS, 
BST1, GAK, and LRRK2, which are associated with sporadic PD, are also defined. In 
a meta-analysis of various GWAS studies, five new loci identified to be associated 
with idiopathic PD were identified. ACMSD, STK39, MCCC1/LAMP3, SYT11, and 
CCDC62/HIP1R loci are found among these loci [20]. SNCA mutations contribute 
to PD development as a result of amino acid displacements and configuration 
changes in the encoded protein [41, 42].
Mata et al. found that SNCA gene polymorphisms were important risk factors 
for PD development risk. In a study conducted by Mata et al., a significant rela-
tionship was found between SNCA plasma levels and rs356219 single-nucleotide 
gene polymorphism [43]. In a study conducted with the Korean population, it was 
determined that the G allele of rs356219 gene polymorphism was associated with 
the risk of PD development [44]. In studies conducted with populations of North 
America, Spain, Russia, and China, rs356219 gene polymorphism was identified as 
a genetic risk factor for PD development risk [26].
In several families of Greek origin and in families of Asian, Swedish, and Polish 
origins, p.Ala53Thr polymorphism, one of the rare mutations in the SNCA gene, 
was detected [6].
In a study that performed to investigate the relationship between rs2301134, 
rs2301135, rs356221, and rs11931074 gene polymorphisms and PD development 
risk, the significant relationship was determined between two promoter poly-
morphisms of the SNCA gene (rs2301134 and rs2301135 gene polymorphisms) 
and PD development risk. In this study, genotype frequencies in rs11931074 gene 
polymorphism in 3′ UTR region of SNCA gene were found to be significantly 
different in patient and control groups. In this study conducted with the Iranian 
population, SNCA gene polymorphisms were identified as a genetic risk factor 
in PD development. In another study, the relationships between the rs2301134, 
rs2301135, rs11931074, and rs356221 gene polymorphisms and the risk of PD 
development were determined in the SNCA gene. In this study, CC genotype and 
C allele of rs2301134 gene polymorphism were found to be related to increased PD 
risk. In addition, CC genotype and C allele of rs2301135 gene polymorphism and 
GG genotype of rs11931074 gene polymorphism were determined to be associated 
with decreased PD [6]. In another study conducted with the Han-Chinese popula-
tion, rs2301135 gene polymorphism was found to be an important risk factor for 
sporadic PD development. However, rs356221 gene polymorphism was not effective 
in PD development [45]. Mata et al. also found that SNCA gene polymorphisms 
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were important risk factors for PD development risk [43]. A meta-analysis study 
to determine 10 candidate single-nucleotide polymorphisms of the SNCA gene 
showed a significant relationship between rs11931074 gene polymorphism and PD 
development risk [28]. In a study conducted in the United States, it was found that 
some single-nucleotide gene polymorphisms in the SNCA gene were associated 
with the risk of PD development, but no significant relationship was determined 
between rs11931074 gene polymorphism and PD development risk [46]. In a study 
conducted with a South American Brazilian population, the relationship between 
rs2583988, rs356219, rs2736990, and rs11931074 gene polymorphisms and the risk 
of PD development was investigated, and the significant relationship was deter-
mined between rs356219 gene polymorphism and increased cognitive disorder in 
PD patients [13]. In studies conducted with European and North American popula-
tions, rs2736990 gene polymorphism has been identified as a genetic risk factor in 
PD development [47]. In another study conducted with a Chinese population, a 
significant relationship was found between the T allele of the rs11931074 polymor-
phism of the SNCA gene and the G allele and PD risk of the rs894278 polymor-
phism. G allele of gene polymorphism of rs11931074 was found associated with 
decreased progression PD risk [29]. Primer sequences for rs2301134, rs2301135, 
rs356221, and rs11931074 gene polymorphisms are presented in Table 1 [7].
In a study conducted by Yu et al. with Han-Chinese population, a significant 
relationship was found between the risk of PD development and the polymorphism 
of rs7684318, which is the intronic polymorphism of the SNCA gene [48].
Rep 1, a complex microsatellite repeat of about 10 kilobases in length, is located 
in the translation start region of the SNCA gene. In some studies, a significant 
relationship was found between specific SNCA-Rep 1 alleles and the risk of late 
onset idiopathic PD development. However, there are also studies indicating that 
Rep 1 risk alleles are not a genetic risk factor for the development of idiopathic 
PD or that these risk alleles and PD development are inversely related [49]. Rep 1 
polymorphic microsatellite repeat is localized in the promoter region (above 10 kb 
the transcription start site) of the SNCA gene [49]. Rep 1–261 is a microsatellite 
polymorphic variant associated with an increase in SNCA mRNA levels [47]. There 
are two common Rep 1 alleles as 251 and 261 bp in length, and functional assays 
about these alleles were performed. According to these functional analyses, while a 
significant relationship was found between the risky allele with a length of 261 bp 
and the upregulation of SNCA gene expression, a significant relationship was found 
SNPs Forward primer (5′-3′) Reverse primer (5′-3′)
rs2301134 F1: AAAGGGTCCTGAGGGTGCAA
F0: CTGAAATTTAATCACGGTC 
ACAGGTTA
R1: CCTGTGACTCTTCCTTAGTAG 
TCTCACC
R0: GAAAAGCCTTAGGACCGCTTGT
rs2301135 F: TCCACAAGAGTGCTCGTGAC R1:CTGATTTGTCAGCGCTTCTG
R2: CTGATTTGTCAGCGCTTCTC
rs356221 F1: GTTCATAAGAGAAG 
CCATCCTACTA
F0: CATGGGTTAGGTTTCATTTTGT
R1: GTTGATCTGCAACTATAGGT 
TAAGAA
R0: ATTGGAAGCAGTTAAACCACAT
rs11931074 F1: AATTGTGAATATGTCTTTGACCGG
F0: ATTCTGTCACTGGGTAGGCAGA
R1: CAGCCTTCCAAATCATAAT 
TCCTTA
R0: TCTGTAGAAAGAACCCATTTGGC
PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism.
Table 1. 
Primer sequences used in PCR for single-nucleotide polymorphisms (rs2301134, rs2301135, rs356221, and 
rs11931074).
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between protective variant 259 bp length and decreased SNCA gene expression 
[49]. In addition, variability in the length of the Rep 1 repeat sequence is associated 
with PD susceptibility. Genotypes containing 263 bp allele of this sequence were 
associated with increased risk of PD development, and genotypes containing 259 bp 
allele were associated with decreased risk of PD development [42]. Changes in 
the promoter region and genetic variations in 30 untranslated SNCA gene regions 
have been associated with susceptibility to PD [49]. In the SNCA promoter (SNCA-
Rep 1), it was determined that the localized Rep 1 and 3′ untranslated region 
polymorphisms interfered with the transcription binding regions and played an 
important role in increasing PD susceptibility. Thus, target regions of miRNAs that 
alter SNCA gene expression are formed or disappear [26]. The significant difference 
was determined between Rep 1–259 allele and low levels of SNCA mRNA in post-
mortem brain tissues of patients with PD. Rep 1 microsatellite repeat and rs2583988, 
rs2619363, rs2619364 gene polymorphisms were found to be a relationship between. 
In a study conducted with a population selected from Belgium, Germany, and 
Serbia, the relationship was found between Rep 1 microsatellite repeat; rs2583988, 
rs2619363, and rs2619364 gene polymorphisms; and PD. In a study conducted with 
German and Japanese populations, it was observed that there was a link between 
intron 4 and 5′ and 3′ untranslated regions (UTRs) in the SNCA gene [6]. In a 
Russian population study, TT genotype of rs2583988 and rs2619363 gene poly-
morphisms and the GG genotype of rs2619364 gene polymorphism were found to 
be associated with higher levels of SNCA mRNA [47]. There are many small-scale 
studies aimed at investigating this relationship, and also, in a meta-analysis study 
conducted by Maraganore et al., in a large population selected from 11 different 
regions, the relationship between the rep 1 gene polymorphism and the risk of PD 
development has been proven [42].
In an analysis with the Caucasus population to investigate the relationship between 
12 single-nucleotide polymorphisms and PD, including the whole SNCA gene region, 
it was determined that signals were collected in a 24 kb-long region in the middle of 
intron 4 of the SNCA gene, and it was determined that these signals were confirmed 
by haplotype analysis showing the presence of a strong protective allele [42].
In addition to these gene polymorphisms, SNCA gene polymorphisms which are 
known to be associated with PD include rs104893875 (G > A), rs104893877 (G > A), 
and rs104893878 (G > C) gene polymorphisms. It has been reported that the polymor-
phism rs104893875 (G > A) has been identified primarily in a multinational Spanish 
family. The significant relationship was determined between rs104893875 (G > A) 
gene polymorphism and increased SNCA protein aggregation. In another study con-
ducted with the Swedish population, as a result of rs104893877 (G > A) mutation, PD 
and encephalopathy with cortical involvement develop. Immunoreactive Lewy neu-
rites were detected in brain stem pigmented nuclei, the hippocampus, and temporal 
neocortexes of PD patients in whom this gene polymorphism was detected. In a study 
that is significant relationship between rs104893878 (G > C) gene polymorphism and 
autosomal dominant PD, hypometabolism was determined in frontal, parietal, and 
left temporal cortexes of PD patients in whom this polymorphism was detected. As a 
result of postmortem examination of brain slices of these patients, Lewy bodies and 
neurodegeneration developed and correspondingly identified. Primer sequences for 
rs104893875 (G/A), rs104893877 (G > A), and rs104893878 (G > C) gene polymor-
phisms are presented in Table 2 [38].
There are three missense mutations, A53T, A30P, and E46K, as the most com-
mon pathogenic changes of the SNCA gene. In a study conducted with the Mexican 
Mestizos population, a significant relationship was determined between the 
rs1801133 and rs3857059 allelic variations of the SNCA gene and the risk of PD devel-
opment. In addition, GG genotype of rs3857059 gene polymorphism was found to be 
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a genetic risk factor for PD development [50]. While A18T and A29S missense muta-
tions in patients with sporadic PD; A53T, A30P, E46K, and H50Q missense mutations 
in familial PD patients have been described. Dual and triple copies of the SNCA locus 
known to be associated with PD severity cause familial Parkinsonism [26].
There are studies showing that there are significant relationships between 
some polymorphisms in the SNCA gene and the risk of sporadic PD development. 
It is also known that these polymorphisms are associated with increased levels of 
plasmatic SNCA. Tyrosine hydroxylase activity and dopamine release decrease as 
a result of SNCA overexpression. In order to investigate the relationship between 
SNCA gene polymorphisms and the risk of PD development, different results have 
been obtained in studies performed with different populations [13].
6. Conclusions
It is known that environmental and genetic factors play a role together in PD 
pathogenesis. Several studies have been carried out to investigate the relationship 
between gene polymorphisms and PD development risk, which are important 
among genetic factors, and different results have been obtained in these studies. It 
is thought that the differences in the results of these studies are due to of PD patient 
and healthy control groups’ different selection criteria and different race and popu-
lations. The identification of genetic polymorphisms that play an important role in 
the development of PD will enable us to have knowledge about the mechanism of 
PD. In addition, new treatment methods can be improved in order to prevent PD. By 
increasing the number of PD patients and healthy controls, different results can 
be obtained in studies with larger populations. As a result, in studies aimed at the 
relationship between SNCA gene polymorphisms and the risk of PD development, 
some of the SNCA gene polymorphisms were found to be genetic risk factors for PD 
development and play an important role in the pathogenesis of the disease.
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SNPs Forward primer (5′-3′) Reverse primer (5′-3′)
rs104893875 
(G/A)
GGCCCCGGTGTTATCTCAT  
(SN-75-CF) TTGTAGGCTCCAAAACCATGG 
(SN-75-GF)
AATTCAAAGCCCTCATTA 
TTCTTGG (SN-75-CR) CACCATG 
CACCACTCCCTT (SN-75-AR)
rs104893877 
(G > A)
GGCCCCGGTGTTATCTCAT (SN-75-CF) 
GGAGTGGTGCATGGTGAGA (SN-77-AF)
AATTCAAAGCCCTCATTATT 
CTTGG (SN-75-CR) 
GCACAATGGAGCTTACCTGTAGC  
(SN-77-GR)
rs104893878 
(G > C)
TCCGTGGTTAGGTGGCTAGA (SN-78-CF) 
ACCAAACAGGGTGTGGCAGAAGCAG 
(SN-78-GF)
CACACGTTCACATTCACCTACCT  
(SN-78-CR1) ACCCTCTTTTGT 
CTTTCCAGC (SN-78-CR2)
PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism.
Table 2. 
Primer sequences used in PCR for single-nucleotide polymorphisms [rs104893875 (G/A), rs104893877 (G > A), 
and rs104893878 (G > C)].
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